查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1293814

流感疫苗市場：按疫苗類型、年齡組、給藥途徑、分銷渠道 - 俄羅斯-烏克蘭衝突和高通脹 - 2023-2030 年全球預測

Influenza Vaccine Market by Vaccine Type, Age Group, Administration Route, Distribution Channel - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球流感疫苗市場預計將大幅增長，預計 2023 年將達到 7921.37 百萬美元，複合年增長率為 8.97%，2030 年將達到 14491.61 百萬美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球流感疫苗市場至關重要。 通過檢查業務戰略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的具體需求做出明智的決策。 這種高級分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場份額分析

市場份額分析可以深入了解供應商在特定市場區域的當前狀態。 比較供應商對整體收入、客戶群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場份額時的表現以及面臨的情況。 該分析還揭示了特定行業的競爭程度、積累和分散的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要公司所服務的市場的全面信息。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細信息，並分析其在成熟市場領域的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新開發和投資的詳細信息。

4. 市場趨勢：全面了解 COVID-19、俄羅斯-烏克蘭衝突和高通脹的累積影響。

5.競爭評估和信息：對主要公司的市場份額、戰略、產品、認證、監管狀況、專利狀況、製造能力進行綜合評估。

6. 產品開發和創新：提供對未來技術、研發活動和突破性產品開發的見解。

此報告回答了以下問題：

1.全球流感疫苗市場規模及預測是多少？

2. 在預測期內，COVID-19 對全球流感疫苗市場的抑制因素和影響是什麼？

3. 在預測期內，全球流感疫苗市場需要投資哪些產品/細分市場/應用/領域？

4.你們在全球流感疫苗市場的競爭策略是什麼？

5.全球流感疫苗市場的技術趨勢和監管框架是什麼？

6.全球流感疫苗市場主要廠商的市場份額是多少？

7.什麼形式和戰略舉措被認為適合進入全球流感疫苗市場？

目錄

第一章前言

第二章研究方法

第 3 章執行摘要

第四章市場概述

第 5 章市場洞察

  • 市場動態
    • 驅動程序
      • 呼吸道疾病患病率上升
      • 疫苗接種作為預防流感病毒感染的主要公共衛生措施
      • 季節性流感臨床試驗和疫苗開發正在進行中
      • 政府支持呼吸系統健康的舉措
    • 抑制因素
      • 配送基礎設施不足且意識有限
    • 機會
      • 主要市場參與者的研發費用增加
      • 通過分銷和開發合作提高疫苗的供應量
      • 幾種針對動物甲型流感病毒的候選疫苗正在開發中
    • 作業
      • 客戶對呼吸道疾病疫苗的信任和信心
      • 庫存持續波動，疫苗研發麵臨挑戰
  • 市場趨勢
  • 新冠肺炎 (COVID-19) 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通脹的累積影響
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 監管框架
  • 客戶定制
    • 新型冠狀病毒：關注積極疫苗研發
    • 免疫接種過渡到零售藥店

第六章按疫苗類型劃分的流感疫苗市場

  • 滅活疫苗
  • 活疫苗
  • 重組

第七章流感疫苗市場：按年齡組

  • 青少年免疫接種
  • 成人免疫接種
  • 嬰兒免疫接種

第八章按給藥途徑劃分的流感疫苗市場

  • 肌肉注射
  • 鼻內
  • 口頭

第 9 章流感疫苗市場：按分銷渠道劃分

  • 政府衛生服務
  • 醫院和診所
  • 零售藥店
  • 急診室

第10章美洲流感疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區流感疫苗市場

  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲流感疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 意大利
  • 荷蘭
  • 尼日利亞
  • 挪威
  • 波蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合酋長國
  • 英國

第13章競爭態勢

  • FPNV定位矩陣
  • 市場份額分析：按主要公司劃分
  • 競爭情景分析：主要公司

第14章上市公司名單

第15章附錄

  • 討論指南
  • 關於許可證和價格
Product Code: MRR-032A67D913F0

The Global Influenza Vaccine Market is forecasted to grow significantly, with a projected USD 7,921.37 million in 2023 at a CAGR of 8.97% and expected to reach a staggering USD 14,491.61 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Influenza Vaccine Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Influenza Vaccine Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Vaccine Type, market is studied across Inactivated, Live Attenuated, and Recombinant. The Recombinant is projected to witness significant market share during forecast period.

Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination. The Infant Vaccination is projected to witness significant market share during forecast period.

Based on Administration Route, market is studied across Intramuscular, Intranasal, and Oral. The Intranasal is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Government Medical Office, Hospital & Clinic, Retail Pharmacy, and Urgent Care Unit. The Urgent Care Unit is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 38.17% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Influenza Vaccine Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Influenza Vaccine Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Influenza Vaccine Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Influenza Vaccine Market?

4. What is the competitive strategic window for opportunities in the Global Influenza Vaccine Market?

5. What are the technology trends and regulatory frameworks in the Global Influenza Vaccine Market?

6. What is the market share of the leading vendors in the Global Influenza Vaccine Market?

7. What modes and strategic moves are considered suitable for entering the Global Influenza Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Influenza Vaccine Market, by Vaccine Type, 2022 vs 2030
  • 4.3. Influenza Vaccine Market, by Age Group, 2022 vs 2030
  • 4.4. Influenza Vaccine Market, by Administration Route, 2022 vs 2030
  • 4.5. Influenza Vaccine Market, by Distribution Channel, 2022 vs 2030
  • 4.6. Influenza Vaccine Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Prevalence of Respiratory Disorders
      • 5.1.1.2. Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
      • 5.1.1.3. Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
      • 5.1.1.4. Government Initiatives Supporting Respiratory Health
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of Inadequate Delivery Infrastructure & Limited Awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D Expenditure by Leading Market Players
      • 5.1.3.2. Increasing Vaccine Availability through Distribution and Development Collaborations
      • 5.1.3.3. Several Vaccine Candidates under Development against Animal Influenza A Virus
    • 5.1.4. Challenges
      • 5.1.4.1. Customers Trust and Confidence in Respiratory Disease Vaccination
      • 5.1.4.2. Vaccine Research and Development are getting Challenged by the Constant Variations in Strains
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization
    • 5.9.1. COVID: Eye on Proactive Vaccine Development
    • 5.9.2. Shift to Retail Pharmacies for Immunizations

6. Influenza Vaccine Market, by Vaccine Type

  • 6.1. Introduction
  • 6.2. Inactivated
  • 6.3. Live Attenuated
  • 6.4. Recombinant

7. Influenza Vaccine Market, by Age Group

  • 7.1. Introduction
  • 7.2. Adolescent Vaccination
  • 7.3. Adult Vaccination
  • 7.4. Infant Vaccination

8. Influenza Vaccine Market, by Administration Route

  • 8.1. Introduction
  • 8.2. Intramuscular
  • 8.3. Intranasal
  • 8.4. Oral

9. Influenza Vaccine Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Government Medical Office
  • 9.3. Hospital & Clinic
  • 9.4. Retail Pharmacy
  • 9.5. Urgent Care Unit

10. Americas Influenza Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Influenza Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Influenza Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. List of Company Mentioned

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing

1. Abbott Laboratories

2. AstraZeneca PLC

3. Bayer AG

4. BioDiem

5. BiondVax Pharmaceuticals Ltd.

6. Bristol-Myers Squibb Company

7. CanSino Biologics Inc.

8. Daiichi Sankyo Company, Limited

9. Emergent BioSolutions Inc.

10. Eurocept Group

11. Fluart Innovative Vaccines Kft.

12. Gamma Vaccines Pty Ltd

13. GlaxoSmithKline PLC

14. Johnson & Johnson

15. Merck & Co., Inc.

16. Pfizer Inc.

17. Sanofi S.A.

18. Seqirus GmbH

19. Serum Institute of India Pvt. Ltd.

20. Sinovac Biotech Ltd.

21. Swedish Orphan Biovitrum AB

LIST OF FIGURES

  • FIGURE 1. INFLUENZA VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. INFLUENZA VACCINE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2022 VS 2030 (%)
  • FIGURE 5. INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2022 VS 2030 (%)
  • FIGURE 6. INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2022 VS 2030 (%)
  • FIGURE 7. INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 8. INFLUENZA VACCINE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 9. INFLUENZA VACCINE MARKET DYNAMICS
  • FIGURE 10. INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 19. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. INFLUENZA VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 9. INFLUENZA VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. INFLUENZA VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. INFLUENZA VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 13. INFLUENZA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. INFLUENZA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. INFLUENZA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. INFLUENZA VACCINE MARKET SIZE, BY GOVERNMENT MEDICAL OFFICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL & CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. INFLUENZA VACCINE MARKET SIZE, BY URGENT CARE UNIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 190. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 191. INFLUENZA VACCINE MARKET LICENSE & PRICING